Prevalence of Keratoconus in Inflammatory Bowel Diseases
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 201
- Primary Endpoint
- Absence or presence of keratoconus in IBD patients
Study Overview
Brief Summary
A retrospective study has shown the association between the inflammatory bowel diseases (IBD) and the presence of a keratoconus. This new study will measure the prevalence of keratoconus and follow its activity in patients affected by IBD and followed up in hepatology-gastroenterology department at Nancy Hospital. The prevalence of keratoconus will be compared to known data of literature about general population.
The secondary purpose is to search for a relationship between the presence of a keratoconus and activity criteria of IBD.
Perspectives are a systematic screening for keratoconus in patients affected by IBD with the amelioration of the ophthalmologic care of IBD patients and confirmation of the recent hypothesis of inflammatory origin of keratoconus.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Informed consent
- •Affiliation to social security plan
- •Diagnosis of IBD since more than 3 years, under treatment or not
Exclusion Criteria
- •Protected person
- •Pregnant or breastfeeding women
- •Person in life-and-death emergency
- •Person deprived of liberty
- •Refusal to remove contact lenses, where necessary
Arms & Interventions
Keratoconus and IBD
Opthalmologic measure with DM OPD scan III (Nidek)
Intervention: Opthalmologic measure with DM OPD scan III (Nidek) (Device)
Outcomes
Primary Outcomes
Absence or presence of keratoconus in IBD patients
Time Frame: day 0
Data from OPD scan III corneal analyzer according to Rabinowitz and Klyce Maeda criteria. The presence of a keratoconus in at least one eye is considered positive.
Secondary Outcomes
- IBD clinical features using the Montreal classification for IBD(day 0)